Journal of Medicinal Chemistry · 2018 · 48 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyAntimicrobial ResistanceDrug DesignDrug DiscoveryAntibacterial AgentsAntibacterial PharmacologyAntibacterial ResistanceAntibacterial TherapyAntibiotic ResistanceEnzyme InhibitionAcinetobacter Baumannii ResistanceAntibacterial Drug DevelopmentAntibiotic DiscoveryAntibiotic Effects On GrowthAntimicrobial Drug DevelopmentAntitrypanosomal TherapyNovel Antibacterial AgentsNovel Antibacterial Drug Discovery
Extending from a study we recently published examining the antitrypanosomal effects of a series of GroEL/ES inhibitors based on a pseudosymmetrical bis-sulfonamido-2-phenylbenzoxazole scaffold, here, we report the antibiotic effects of asymmetric analogs of this scaffold against a panel of bacteria known as the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). While GroEL/ES inhibitors were largely ineffective against K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae (Gram-negative bacteria), many analogs were potent inhibitors of E. faecium and S. aureus proliferation (Gram-positive bacteria, EC50 values of the most potent analogs were in the 1–2 μM range). Furthermore, even though some compounds inhibit human HSP60/10 biochemical functions in vitro (IC50 values in the 1–10 μM range), many of these exhibited moderate to low cytotoxicity to human liver and kidney cells (CC50 values > 20 μM).
23
The crystal structure of the bacterial chaperonln GroEL at 2.8 Å
K. Braig, Zbyszek Otwinowski, Rashmi S. Hegde et al. · Nature · 1994 · 1.3K citations
Residues in chaperonin GroEL required for polypeptide binding and release
Wayne A. Fenton, Yechezkel Kashi, Krystyna Furtak et al. · Nature · 1994 · 642 citations